- Home
- KLAC vs ABBV Comparison
KLAC vs ABBV Comparison
Compare KLAC & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLAC | ABBV |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0B | 451.5B |
| IPO Year | 1994 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KLAC | ABBV |
|---|---|---|
| Price | $169.92 | $285.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 30 |
| Target Price | $232.77 | ★ $282.61 |
| AVG Volume (30 Days) | ★ 6.7M | 2.8M |
| Earning Date | 10-28-2026 | 10-30-2026 |
| Dividend Yield | 0.53% | ★ 2.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.66 | 2.42 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $33.60 | $10.57 |
| Revenue Next Year | $18.92 | $8.79 |
| P/E Ratio | ★ $47.68 | $116.90 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $165.93 | $190.75 |
| 52 Week High | $2,431.29 | $291.40 |
Technical Indicators
Market Signals| Indicator | KLAC | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 70.57 |
| Support Level | $167.59 | $243.68 |
| Resistance Level | $211.23 | N/A |
| Average True Range (ATR) | 6.59 | 6.45 |
| MACD | -1.54 | 1.66 |
| Stochastic Oscillator | 4.74 | 80.37 |
Price Performance
Historical ComparisonAbout KLAC KLA Corporation
KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.